近年来，膀胱癌（BC）的发病率不断增加，但患者预后不佳。临床上，BC的治疗仍以手术联合放化疗为主。然而，随着肿瘤细胞的化疗耐药性越来越明显，迫切需要寻找更有效的BC治疗方案。随着表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）在各类肿瘤疾病中的应用日益广泛和受到越来越多的关注，EGFR-TKI已被认为是未来新的治疗方向。在这项研究中，研究团队使用AG1478（一种EGFR-TKI）来干预BC细胞系T24。结果发现，细胞活性统计上降低，细胞凋亡增强，细胞主要停滞在G0/G1期，证实了EGFR-TKIs未来治疗BC的潜力。此外，研究团队进一步观察到AG1478还促进T24细胞焦亡，其机制与诱导线粒体氧化应激损伤有关。该研究结果为未来EGFR-TKI在BC的应用奠定了更可靠的基础。

In recent years, bladder carcinoma (BC) has shown an increasing incidence, with poor patient outcomes. In clinical practice, BC is still mainly treated by surgery combined with chemoradiotherapy. However, as chemotherapy resistance of tumor cells becomes more and more obvious, it is urgent to find more effective BC treatment regimes. With the increasing application and growing attention paid to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in various neoplastic diseases, EGFR-TKIs have been considered as a new treatment direction in the future. In this study, the research team used AG1478, an EGFR-TKI, to intervene with the BC cell line T24. It was found that the cell activity was statistically decreased, the apoptosis was enhanced, and the cells were dominantly arrested in the G0/G1 phase, confirming the future therapeutic potential of EGFR-TKIs in BC. Besides, the research team further observed that AG1478 also promoted pyroptosis in T24 cells, and its mechanism is related to the induction of mitochondrial oxidative stress damage. The findings lay a more reliable foundation for the future application of EGFR-TKIs in BC.